Recherche intégrée pour une médecine personnalisée en oncologie digestive : M. Ychou/A. Thierry

Liste des Publications

Hofman P, Dagher G, Laurent-Puig P, Hugo-Marquette C, Barlesi F, Bibeau F, Clément B [Tumor banks and complex data management: Current and future challenges]. Ann Pathol. Feb 25, 2019. doi:10.1016/j.annpat.2019.01.017

Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Azria D [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother. Aug 20, 2019. doi:10.1016/j.canrad.2019.07.159

Bibeau F [Biomarker, what is the pathologist's role?]. Ann Pathol. 2019;39(3):177-178. doi:10.1016/j.annpat.2019.05.002

Badoual C, Bibeau F [Augmented pathology, future or present ?]. Ann Pathol. Mar 14, 2019. doi:10.1016/j.annpat.2019.02.009

Lutz M, Zalcberg J, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch H, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider P, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner A, Otto F The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur. J. Cancer. 2019;112. doi:10.1016/j.ejca.2019.01.106

Assenat E, Pageaux G-P, Peron J-M, Bécouarn Y, Seitz J-F, Merle P, Blanc J-F, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br. J. Cancer. Apr 04, 2019. doi:10.1038/s41416-019-0443-4

Nougaret S, Jhaveri K, Kassam Z, Lall C, Kim D Rectal cancer MR staging: pearls and pitfalls at baseline examination. Abdom Radiol (NY). May 21, 2019. doi:10.1007/s00261-019-02024-0

Hope T, Gollub M, Arya S, Bates D, Ganeshan D, Harisinghani M, Jhaveri K, Kassam Z, Kim D, Korngold E, Lalwani N, Moreno C, Nougaret S, Paroder V, Paspulati R, Golia Pernicka J, Petkovska I, Pickhardt P, Rauch G, Rosenthal M, Sheedy S, Horvat N Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel. Abdom Radiol (NY). Aug 06, 2019. doi:10.1007/s00261-019-02170-5

Otandault A, Anker P, Al Amir Dache Z, Guillaumon V, Meddeb R, Pastor B, Pisareva E, Sanchez C, Tanos R, Tousch G, Schwarzenbach H, Thierry A Recent advances in Circulating Nucleic Acids in oncology. Ann. Oncol.. Feb 07, 2019. doi:10.1093/annonc/mdz031

Mazard T, Assenat E, Dupuy M, Mollevi C, René A, Adenis A, Chauffert B, Boucher E, Francois E, Pierga J-Y, Ducreux M, Ychou M, Gallix B Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. Dig Liver Dis. May 10, 2019. doi:10.1016/j.dld.2019.03.028

Meddeb R, Dache Z, Thezenas S, Otandault A, Tanos R, Pastor B, Sanchez C, Azzi J, Tousch G, Azan S, Mollevi C, Adenis A, El Messaoudi S, Blache P, Thierry A Quantifying circulating cell-free DNA in humans. Sci Rep. 2019;9(1):5220. doi:10.1038/s41598-019-41593-4

Boutanos C, Capdepont M, Svrcek M, Thélu F, Guedj N, Poizat F, Bibeau F, Turlin B, Rousseau A, Bardier A, Selves J, Desrousseaux M, Le Pessot F, Bonhomme B, Laverrière M-H, Julié C, Eyremandi R-P, Stanislas S, Bazille C, Daubech A, Lazure T, Bordier M-S, Demoures A, Rullier A National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016. Virchows Arch.. 2019;474(5):561-568. doi:10.1007/s00428-019-02534-8

Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud J, Yguel C, Mazières J, Lepage A-L, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette C-H, Sabourin J-C, Ilié M, Hofman P Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients. J Thorac Oncol. Apr 15, 2019. doi:10.1016/j.jtho.2019.03.024

Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia J-P, Picquenot J-M, Thomas J, Tille J-C, Slaets L, Bodmer A, Bergh J, Cameron D Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. Br. J. Cancer. Mar 22, 2019. doi:10.1038/s41416-019-0420-y

Dupasquier S, Blache P, Picque Lasorsa L, Zhao H, Abraham J-D, Haigh J, Ychou M, Prévostel C Modulating PKC? Activity to Target Wnt/?-Catenin Signaling in Colon Cancer. Cancers (Basel). 2019;11(5). doi:10.3390/cancers11050693

Abboud K, Brunel M, Ducreux M, Eveno C, Glehen O, Goéré D, Gornet J-M, Lefevre J, Mariani P, Pinto A, Quenet F, Sgarbura O, Ychou M, Pocard M Management of colorectal peritoneal metastases: Expert opinion. J Visc Surg. Aug 26, 2019. doi:10.1016/j.jviscsurg.2019.08.002

Ganeshan D, Nougaret S, Korngold E, Rauch G, Moreno C Locally recurrent rectal cancer: what the radiologist should know. Abdom Radiol (NY). Apr 05, 2019. doi:10.1007/s00261-019-02003-5

Kato K, Shah M, Enzinger P, Bennouna J, Shen L, Adenis A, Sun J-M, Cho B, Özgüro?lu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean L, Shah S, Doi T KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15(10):1057-1066. doi:10.2217/fon-2018-0609

Boige V, Mollevi C, Gourgou S, Azria D, Seitz J-F, Vincent M, Bigot L, Juzyna B, Miran I, Gerard J-P, Laurent-Puig P Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. Int. J. Cancer. May 20, 2019. doi:10.1002/ijc.32417

Shergill A, Camacho A, Horowitz J, Jha P, Ascher S, Berchmans E, Slama J, Nougaret S, Wasnik A, Robbins J, Dighe M, Wang C, Nimhuircheartaigh J, Phillips J, Menias C, Brook O Imaging of transgender patients: expected findings and complications of gender reassignment therapy. Abdom Radiol (NY). Jun 01, 2019. doi:10.1007/s00261-019-02061-9

Sun S, Bonaffini P, Nougaret S, Fournier L, Dohan A, Chong J, Smith J, Addley H, Reinhold C How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. Aug 16, 2019. doi:10.1016/j.diii.2019.07.007

Meddeb R, Pisareva E, Thierry A Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin. Chem.. Feb 21, 2019. doi:10.1373/clinchem.2018.298323

Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard J-Y, Andre F, Scarpa A ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann. Oncol.. May 06, 2019. doi:10.1093/annonc/mdz116

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet J, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. Clin Colorectal Cancer. 2019;18(3):200-208.e1. doi:10.1016/j.clcc.2019.04.006

Nougaret S, Castan F, de Forges H, Vargas H, Gallix B, Gourgou S, Rouanet P Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial. Br J Surg. Aug 22, 2019. doi:10.1002/bjs.11233

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés